Skip Navigation LinksHome > August 2013 - Volume 29 - Issue 8 > Bowel Function After Tapentadol and Oxycodone Immediate Rele...
Clinical Journal of Pain:
doi: 10.1097/AJP.0b013e318274b695
Original Articles

Bowel Function After Tapentadol and Oxycodone Immediate Release (IR) Treatment in Patients With Low Back or Osteoarthritis Pain

Kwong, Winghan J. PharmD, PhD*; Hammond, Geoffrey PhD; Upmalis, David MD; Okamoto, Akiko ScD; Yang, Min PhD; Kavanagh, Shane MSc§

Collapse Box

Abstract

Objectives:

Constipation is a common side effect of opioid therapy. Tapentadol immediate release (IR) was better tolerated than oxycodone IR in 2 clinical trials involving patients with low back or osteoarthritis pain. The objective of this study was to examine patient-reported bowel function during those trials.

Methods:

Bowel function was assessed during secondary post hoc analyses using: the bowel movement questionnaire (BMQ; 10-d trial); the Patient Assessment of Constipation Symptoms questionnaire (PAC-SYM; 90-day trial); and laxative use (both trials). Random effects maximum likelihood regressions were run to examine PAC-SYM data. BMQ data were analyzed using 1-way analyses of variance and a multinomial logistic regression. Rates of laxative use were compared using χ2 statistics.

Results:

The 10- and 90-day trials consistently showed that tapentadol IR caused less impairment of bowel function than oxycodone IR. BMQ data were comparable between patients receiving tapentadol IR and placebo, and better versus oxycodone IR including: lower proportion of days where bowel movement was absent (P<0.05); lower risks of reporting hard stools (P<0.001); and moderate or severe straining (P<0.001). All PAC-SYM summary scores (abdominal, rectal, stool, overall) indicated fewer symptoms among patients receiving tapentadol IR versus oxycodone IR (P<0.001). In both trials, rates of laxative use was lower for tapentadol IR treatment groups versus oxycodone IR (P<0.001).

Discussion:

Patient-reported bowel function associated with tapentadol IR treatment was similar to that associated with placebo (10-d trial) and significantly better than that associated with oxycodone IR treatment (10- and 90-d trials).

Copyright © 2013 by Lippincott Williams & Wilkins

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.